Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Maraviroc

FDA-approved product (tablet, oral), marketed as Maraviroc, Selzentry.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Maraviroc
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • HIV infection
  • HIV-1 infection
  • Viral disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other antivirals
FDA pharmacologic class
CCR5 Co-receptor Antagonist FDA label ↗
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J05AX09

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA47.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli40.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae31.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis51.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Maraviroc in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-9.4 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.8 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.6 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-9.1 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Maraviroc with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Pilot Study Of A Novel Treatment Regimen, Maraviroc + Ritonavir Boosted Atazanavir, In Treatment Naive HIV-Infected Patients

    NCT00827112 · start 2009-03

    Registered record
    Registry ID
    NCT00827112
    Conditions
    Human Immunodeficiency Virus-1
    Interventions
    maraviroc; maraviroc
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2009-03
    Completion
    2011-07
    Enrolment
    129

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHuman Immunodeficiency Virus-1
    Interventionmaraviroc; maraviroc
    PhasePhase 2
    Registry statusCompleted

  • Maraviroc Immune Recovery Study

    NCT00875368 · start 2009-02

    Registered record
    Registry ID
    NCT00875368
    Conditions
    HIV Infections
    Interventions
    maraviroc; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2009-02
    Completion
    2012-08
    Enrolment
    85

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    Interventionmaraviroc; Placebo
    PhasePhase 4
    Registry statusCompleted

  • Adding Maraviroc to Antiretroviral Therapy for Suboptimal CD4 T-Cell Recovery Despite Sustained Virologic Suppression

    NCT00709111 · start 2009-01

    Registered record
    Registry ID
    NCT00709111
    Conditions
    HIV Infections
    Interventions
    Maraviroc
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2009-01
    Completion
    2010-04
    Enrolment
    34

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionMaraviroc
    PhaseNot applicable
    Registry statusCompleted

  • An Interaction Study to Assess Drug Levels in Healthy Adult Subjects

    NCT00764465 · start 2008-10

    Registered record
    Registry ID
    NCT00764465
    Conditions
    Healthy
    Interventions
    Maraviroc; Fosamprenavir; Ritonavir
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2008-10
    Completion
    2008-12
    Enrolment
    45

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionMaraviroc; Fosamprenavir; Ritonavir
    PhasePhase 2
    Registry statusCompleted

  • A Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of Single Oral Doses Of PF-03716539 In Healthy Adult Subjects

    NCT00783484 · start 2008-10

    Registered record
    Registry ID
    NCT00783484
    Conditions
    Healthy Volunteers
    Interventions
    PF-03716539; PF-03716539; PF-03716539; Placebo; PF-03716539; PF-03716539; PF-03716539; Placebo; Midazolam; Midazolam + PF-03716539 (100 mg); Midazolam + PF-03716539 (50 mg); Darunavir; Darunavir + PF-03716539; Maraviroc; Maraviroc +PF-03716539; Maraviroc; Maraviroc +PF-03716539
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2008-10
    Completion
    2009-05
    Enrolment
    37

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteers
    InterventionPF-03716539; PF-03716539; PF-03716539; Placebo +13 more
    PhasePhase 1
    Registry statusCompleted

  • Maraviroc as an Immunomodulatory Drug for Antiretroviral-treated HIV Infected Patients Exhibiting Immunologic Failure

    NCT00735072 · start 2008-09

    Registered record
    Registry ID
    NCT00735072
    Conditions
    HIV Infection
    Interventions
    Placebo; Maraviroc
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2008-09
    Completion
    2010-07
    Enrolment
    45

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infection
    InterventionPlacebo; Maraviroc
    PhasePhase 4
    Registry statusCompleted

  • Kaletra in Combination With Antiretroviral Agents

    NCT01076179 · start 2008-09

    Registered record
    Registry ID
    NCT01076179
    Conditions
    Human Immunodeficiency Virus
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2008-09
    Completion
    2016-01
    Enrolment
    502

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHuman Immunodeficiency Virus
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Maraviroc Compassionate Use

    NCT00719823 · start 2008-08

    Registered record
    Registry ID
    NCT00719823
    Conditions
    Human Immunodeficiency Virus Type 1
    Interventions
    Maraviroc
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Withdrawn
    Start
    2008-08
    Completion
    2010-05
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHuman Immunodeficiency Virus Type 1
    InterventionMaraviroc
    PhasePhase 3
    Registry statusWithdrawn

  • Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Elvitegravir Versus Raltegravir

    NCT00708162 · start 2008-07

    Registered record
    Registry ID
    NCT00708162
    Conditions
    HIV Infection
    Interventions
    Elvitegravir; Raltegravir; EVG placebo; RAL placebo; Background regimen
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2008-07
    Completion
    2015-04
    Enrolment
    724

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infection
    InterventionElvitegravir; Raltegravir; EVG placebo; RAL placebo +1 more
    PhasePhase 3
    Registry statusCompleted

  • Pharmacokinetics, Safety And Toleration Of Maraviroc Administered To Subjects With Various Degrees Of Renal Impaired And Normal Renal Function

    NCT00717067 · start 2008-07

    Registered record
    Registry ID
    NCT00717067
    Conditions
    Human Immunodeficiency Virus (HIV) Infection
    Interventions
    Maraviroc; Maraviroc; Ritonavir; Saquinavir; Maraviroc; Ritonavir; Saquinavir; Maraviroc; Ritonavir; Saquinavir; Maraviroc; Maraviroc; Maraviroc
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2008-07
    Completion
    2008-11
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHuman Immunodeficiency Virus (HIV) Infection
    InterventionMaraviroc; Maraviroc; Ritonavir; Saquinavir +9 more
    PhasePhase 4
    Registry statusCompleted

  • Study in Healthy Males to Measure Maraviroc in Blood, Saliva, Seminal Fluid, and Rectal Tissue

    NCT00775294 · start 2008-05

    Registered record
    Registry ID
    NCT00775294
    Conditions
    HIV/AIDS
    Interventions
    Maraviroc
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2008-05
    Completion
    2010-03
    Enrolment
    14

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV/AIDS
    InterventionMaraviroc
    PhasePhase 1
    Registry statusCompleted

  • Study To Investigate The Hemodynamic Effects Of Single Dose Vardenafil In Subjects Receiving Maraviroc

    NCT00853840 · start 2008-04

    Registered record
    Registry ID
    NCT00853840
    Conditions
    AIDS
    Interventions
    Maraviroc; Vardenafil; Maraviroc; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2008-04
    Completion
    2008-05
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAIDS
    InterventionMaraviroc; Vardenafil; Maraviroc; Placebo
    PhasePhase 4
    Registry statusCompleted

  • Optimizing Treatment for Treatment-Experienced, HIV-Infected People

    NCT00537394 · start 2008-01

    Registered record
    Registry ID
    NCT00537394
    Conditions
    HIV Infections
    Interventions
    Enfuvirtide; Raltegravir; Darunavir; Tipranavir; Etravirine; Maraviroc
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2008-01
    Completion
    2013-04
    Enrolment
    517

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionEnfuvirtide; Raltegravir; Darunavir; Tipranavir +2 more
    PhasePhase 3
    Registry statusCompleted

  • Multicenter, Safety Study Of Maraviroc

    NCT00478231 · start 2007-07

    Registered record
    Registry ID
    NCT00478231
    Conditions
    Acquired Immunodeficiency Syndrome; HIV Infection
    Interventions
    Maraviroc
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2007-07
    Completion
    2010-09
    Enrolment
    209

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcquired Immunodeficiency Syndrome; HIV Infection
    InterventionMaraviroc
    PhasePhase 3
    Registry statusCompleted

  • Multicenter Pilot Study To Define The Marker As An Alternate For Tropism Assay

    NCT00496782 · start 2007-07

    Registered record
    Registry ID
    NCT00496782
    Conditions
    HIV Infections
    Interventions
    maraviroc; Trofile Assay and HIV RNA quantification assay
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2007-07
    Completion
    2008-10
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    Interventionmaraviroc; Trofile Assay and HIV RNA quantification assay
    PhasePhase 1
    Registry statusTerminated